Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that PKCα activation in transgenic mice induces keratinocyte apoptosis and mediates neutrophilic skin inflammation via different pathways, suggesting potential mechanisms for cutaneous inflammatory diseases.

This review discusses the JAK-STAT pathway and the use of FDA-approved JAK inhibitors for autoimmune and inflammatory diseases but reports no new research findings.

In this phase 2 study, baricitinib at 2 mg and 4 mg doses significantly improved hair regrowth in adults with alopecia areata and ≥50% scalp hair loss compared to placebo, without new safety concerns, although the small sample size limits the results' generalizability.

This study found that oral JAK inhibitors, ruxolitinib and tofacitinib, are effective and well-tolerated for treating severe alopecia areata, with a similar degree of hair regrowth and relapse rates, but ruxolitinib induced faster initial hair regrowth.

This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.

This study found that inhibiting PKC-β activity with bisindolylmaleimide reduces pigmentation in the skin and hair of guinea pigs and mice by preventing tyrosinase activation.

In this study, TCDD administered to male rats down-regulated EGF receptor in liver plasma membranes and increased protein kinase activity, suggesting EGF receptor–mediated toxicological effects.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

This review summarizes existing evidence on the efficacy and safety of JAK inhibitors for treating alopecia areata and emphasizes the need for improved topical formulations.

JAK inhibitors might help treat alopecia areata.

This study suggests that polyamines regulate CK2 enzyme activity and its subcellular distribution, as demonstrated in mouse models and cell cultures with elevated levels of ornithine decarboxylase.

Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.

This study found that cyclosporin A stimulates growth in cultured murine hair epithelial cells and reduces protein kinase C expression, suggesting that these actions may contribute to its hair-growing effects.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

This study found that in androgenetic alopecia, reduced stem cell factor production by dermal papilla cells may lead to decreased pigmentation in hair follicles.

This study found that a novel IKZF1 mutation, p.L188V, is linked to juvenile-onset systemic lupus erythematosus and alters B-cell activation by disrupting normal DNA binding.

This study found that overexpressing PKCδ in transgenic mice did not reduce squamous cell carcinoma development induced by UV radiation, despite its effectiveness against TPA-promoted cancer in these mice.

In this study, researchers observed that follicular damage and stem cell loss in frontal fibrosing alopecia may be mediated by immune attacks at the bulge region, suggesting potential for JAK/STAT-targeting treatments to prevent progression.

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.

In this study, procyanidin B-2 and C-1 were found to promote hair growth by selectively inhibiting protein kinase C, supporting their potential use for hair-growing activity.

This study discusses the immune dysregulation observed in individuals with Down syndrome, highlighting their increased risk for autoimmune skin conditions, but does not yet clarify the molecular mechanisms behind this profile.

This review proposes a classification system for childhood hair loss based on clinical appearance, age of onset, and associated symptoms, but reports no new clinical results.

This study found that overexpression of PKCepsilon in mouse epidermis was associated with increased susceptibility to metastatic squamous cell carcinoma, potentially through a mechanism involving tumor necrosis factor-alpha.

This study found that phenyl-imidazole sulfonamide derivatives, particularly ISCK03, inhibited c-kit signaling and promoted depigmentation in various experimental settings, suggesting potential use as skin-whitening agents.

This study suggests that Foxn1 acts as a brake on PKC signaling in keratinocytes, thereby modulating the stages of differentiation by controlling PKC activity.

In this study, severe hair loss occurred in PKC epsilon transgenic mice treated with DFMO during skin tumor prevention, highlighting a link between polyamine biosynthesis, hair follicle maintenance, and metastasis suppression.

This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.

This study found that oral tofacitinib was effective in promoting hair regrowth in patients with alopecia universalis, although further controlled studies are recommended to confirm its safety and efficacy.

This review discusses the role of natural killer cells in the pathogenesis of blistering diseases and proposes further research on their interaction with the skin, reporting no new clinical results.

In this study, ritlecitinib showed sustained effectiveness and a favorable safety profile in treating alopecia areata in patients aged 12 and older over 24 months, with improvements observed in hair and eyebrow regrowth and patient satisfaction.